Long-term randomised comparison of clinical outcomes following ART initiation with triple-nucleoside (Combivir/Abacavir) or NNRTI-based (Combivir/Nevirapine) therapy in Africa: the NORA substudy of the DART trial

A S Walker,P Munderi,Cissy Kityo,A G Babiker,F Ssali,A Reid,Heiner Grosskurth,P Mugyenyi,D M Gibb,C F Gilks

msra（2009）

引用 23|浏览23

暂无评分

摘要

— Death: HR(ABC:NVP) = 0.55 (95% CI 0.24-1.25) p=0.15 — Death/WHO 4: HR(ABC:NVP) = 0.60 (95% CI 0.34-1.05) p=0.07 — Death/WHO 3/4: HR(ABC:NVP) = 0.67 (95% CI 0.46-0.96) p=0.03

查看译文

关键词

question: how does clinical disease progression in abc compare to that in nvp over the longer-term?,health,clinical trials

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要